Joao Tome ́-Carneiro1, Manuel Gonza ́lvez2, Mar Larrosa1, Francisco J. Garc ́ıa-Almagro2, Francisco Avile ́s-Plaza3, Soledad Parra3, Mar ́ıa J. Ya ́n ̃ez-Gasco ́n1, Jose ́ A. Ruiz-Ros2, Mar ́ıa T. Garc ́ıa-Conesa1, Francisco A. Toma ́s-Barbera ́n1 and Juan Carlos Esp ́ın1
1 Research Group on Quality, Safety and Bioactivity of Plant Foods, Department of Food Science and Technology, CEBAS-CSIC, Murcia, Spain
2 Cardiology Service, Morales Meseguer University Hospital, Murcia, Spain
3 Clinical Analyses Service, Virgen de La Arrixaca University Hospital, Murcia, Spain
Scope: The cardioprotective role of resveratrol as part of the human diet is not yet clear. Our aim was to investigate the effect of a grape supplement containing 8 mg resveratrol in oxidized LDL (LDLox), apolipoprotein-B (ApoB), and serum lipids on statin-treated patients in primary cardiovascular disease prevention (PCP).
Methods and results: A triple-blind, randomized, placebo-controlled trial was conducted. Seventy-five patients (three parallel arms) consumed one capsule (350 mg) daily for 6 months containing resveratrol-enriched grape extract (GE-RES, Stilvid⃝R ), grape extract (GE, similar polyphenolic content but no resveratrol), or placebo (maltodextrin). After 6 months, no changes were observed in the placebo group and only LDL cholesterol (LDLc) decreased by 2.9% (p = 0.013) in the GE group. In contrast, LDLc (−4.5%, p = 0.04), ApoB (−9.8%, p = 0.014), LDLox (−20%, p = 0.001), and LDLox/ApoB (−12.5%, p = 0.000) decreased in the Stilvid⃝R group, whereas the ratio non-HDLc (total atherogenic cholesterol load)/ApoB increased (8.5%, p = 0.046). No changes were observed in hepatic, thyroid, and renal function. No adverse effects were observed in any of the patients.
Conclusion: This GE-RES reduced atherogenic markers and might exert additional cardiopro- tection beyond the gold-standard medication in patients from PCP. The presence of resveratrol in the GE was necessary to achieve these effects.
Cardiovascular / Clinical trial / Nutraceutical / Polyphenol / Resveratrol
The first International ReGenera R&D International for Aging Intervention and VCC Preventive Medical Promotion Foundation has been a flashy success.
It has been held in Beijing last June 8, having as topics Gut Microbiota and Health. The keynote speaker was prof. Marotta and the meeting features the most authoritative Asian specialists in the field.
The conference room was fully packed and, most important, about 10.000 physicians and health professionals registered for a live attendance at distance.
The event as covered by the most reputed national TV channels and in the next days a series of interviews followed up.
The organizer, VCC Preventive Medical Promotion Foundation, given this success, is planning further similar top scientific gatherings this year in other locations.
There was a general consensus on the importance to deepen our knowledge in this area as well ass starting providing practical steps forwards an evaluation and phenotypic monitoring of gut microbiota, while envisaging designer pro-prebiotics interventions.